SIRPA and neoplasm: OAd-SIRPα-Fc treatment conferred better antitumor activity than OAd-Siglec10-Fc and OAd-TIGIT-Fc in the MC38 model (Fig. 3b), but OAd-Siglec10-Fc showed satisfactory tumor suppression in the 4T1 model (Fig. 3c).